#diabetes management #Vienna #Austria #SIBIONICS #EASD 2025

Revolutionizing Diabetes Management at EASD 2025

At the prestigious 61st Annual Meeting of the European Association for the Study of Diabetes (EASD), held in Vienna, SiBionics emerged as a pivotal player with its innovative integrated solution comprising Continuous Glucose Monitoring (CGM) and Continuous Ketone Monitoring (CKM) systems. This symposium, under the theme of "CGM + CKM for Better Diabetes Management," attracted notable scholars and specialists from around the globe who engaged in a rich discussion about the future of diabetes care.

Prominent Leaders in Diabetes Research

The event was graced by esteemed keynote speakers, including Prof. Linong Ji from Peking University People's Hospital and Prof. Stefano Genovese from Italy, who co-chaired the conference. Their insights, along with presentations from recognized researchers such as Prof. Andrej Janež (Slovenia), Prof. Nina Jendrike (Germany), and Dr. Yifei Mo (China), provided invaluable perspectives on the evolving landscape of diabetes research and management.

A New Era of Monitoring Technologies

Central to the exhibition were SiBionics’ next-generation devices: the GS3 Continuous Glucose Monitoring system and the KS3 Continuous Ketone Monitoring device. These state-of-the-art products captured significant attention, showcasing their technical capabilities and clinical relevance. Attendees expressed keen interest, engaging in constructive discussions with the SiBionics team on how these devices can enhance real-world diabetes management.

Furthermore, a recent feasibility study revealed that SiBionics’ systems not only meet but exceed the standards set for iCGM (integrated Continuous Glucose Monitoring), excelling across several critical performance metrics. The GS3 system, renowned for its accuracy and reliability, demonstrated remarkable performance, particularly in the hypoglycemic range, surpassing iCGM requirements. This achievement underscores the system's critical role in both clinical decision-making and empowering patients for self-management.

A Leader in Continuous Monitoring Technologies

SiBionics is carving a niche as a leader in the continuous monitoring technology field. Remarkably, it is the only company worldwide commercializing CKM solutions, reflecting its robust research and development capabilities and forward-thinking vision. Looking ahead, SiBionics plans to expand its Continuous Monitoring portfolio, driving innovation and delivering precise, high-quality solutions aimed at improving outcomes for diabetes patients globally.

About SiBionics

Founded in 2015, SiBionics is headquartered in Shenzhen and Irvine, specializing in biosensor innovations. With a passionate team of over 500 employees, including 25% dedicated to research and development, SiBionics is operationally focused on enhancing health management through a fusion of continuous monitoring technologies, smart algorithms, and user-friendly software. The company is dedicated to providing personalized, data-driven healthcare that improves the lives of individuals living with diabetes around the world.

SiBionics' significant presence at EASD 2025 is a testament to its commitment to advancing diabetes management and shaping a healthier future for those affected by this chronic condition.